Johnson & Johnson (JNJ) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Johnson & Johnson (JNJ)

254.66

+9.78 (3.99%)

as of Jun 26, 2026, 8:00:00 pm Market Open.

696 watching

Investor Insights

Jun 28, 2026, 12:00 am

This summary was created by AI, based on 10 opinions in the last 12 months.

Johnson & Johnson (JNJ) has garnered a generally positive outlook from various experts, particularly highlighting its strong performance in pharmaceuticals and medical devices after a recent spin-off of its orthopedics division. The company's robust drug pipeline is considered one of the best in the industry, contributing to a resilient stock performance even amidst market volatility. While there is a legal overhang due to ongoing talcum powder lawsuits, experts suggest that this has diminished in significance. The company's valuation appears reasonable, and many experts encourage buying on weakness, reflecting confidence in future growth prospects. Overall, JNJ is seen as a solid investment, especially for those interested in dividend growth and long-term potential.

Consensus

Positive

Valuation

Fair Value

Similar

BUY

Well rounded in different health areas.

BUY

PAST TOP PICK

(Was a top pick on July 17. No change.) Still likes. A core holding.

DON'T BUY

Expensive now. Good long term hold.

TOP PICK

Great price. Should appreciate 15% a year. Good numbers.

BUY

A good long term hold. Good price.

WAIT

Benefiting from weaker US $. Wait for it to reverse its down trend.

BUY

Bullish. International.No generic drug problems. Good cash flow from a lot of coonsumer products.

DON'T BUY

Great company, but expensive.

BUY

Prefers this and Pfizer over Merk.

BUY

Some good products. Grows well.

BUY

Not cheap. Good stability. Good product development skills.

STRONG BUY

Steady earnings. Demographics on health needs are good.

DON'T BUY

A bit expensive, but a good hold. Buy near $50.

DON'T BUY

Had a nice run. Probably near its top.

Showing 601 to 615 of 626 entries

Most Recent Experts

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Kevin Simpson

Capital Wealth Planning

Bryn Talkington

Requisite Capital Management

Andrey Omelchak

LionGuard Capital Management

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Johnson & Johnson (JNJ)